-
Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.
-
Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.
Siena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. [Read more…]